Long-term statin therapy could be efficacious in reducing the lipoprotein (a) levels in patients with coronary artery disease modified by some traditional risk factors

Xu, Min; Liu, Chang; He, Yao; Yang, Xiangjun; Zhao, Xin

doi:10.21037/jtd.2017.04.32

Cited by 8 publications

(6 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may be because the animals used in this study were It is currently unclear whether the level of Lp (a), a potent risk factor for heart disease, 33 is suppressed by statins, a widely used class of hydroxymethylglutaryl-CoA reductase inhibitors. [34][35][36] SARM-2f showed a tendency to reduce blood Lp (a) levels in monkeys. Further studies are required to confirm this effect.…”

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

A selective androgen receptor modulator SARM‐2f activates androgen receptor, increases lean body mass, and suppresses blood lipid levels in cynomolgus monkeys

Morimoto

Yamaoka

Hara

2020

Pharmacology Res & Perspec

View full text Add to dashboard Cite

SARM‐2f a selective androgen receptor (AR) modulator, increases skeletal muscle mass and locomotor activity in rats. This study aimed to clarify its pharmacological effects in monkeys. In reporter assays, the EC50 values of SARM‐2f for rat, monkey, and human AR were 2.5, 3, and 3.6 nmol/L, respectively; those of testosterone were 12, 3.2, and 11 nmol/L, respectively. A single oral administration (10 mg/kg SARM‐2f) produced a maximal plasma concentration of 3011 ng/mL, with an area under the 24 hours concentration‐time curve of 8152 ng·h/mL in monkeys. Body weight (BW), lean body mass (LBM), and plasma levels of total cholesterol, triglyceride, high‐density lipoprotein cholesterol, low‐density lipoprotein cholesterol, lipoprotein (a), alanine aminotransferase, and asparagine aminotransferase were measured after 4 weeks of treatment with SARM‐2f (1, 3, and 10 mg/kg/day, QD, p.o.) or testosterone enanthate (TE; 2 mg/kg/2 weeks, s.c.) in monkeys. BW and LBM were significantly increased by 12% each by SARM‐2f at 10 mg/kg, and by 5% and 8%, respectively, by TE, but these effects were not statistically significant. Plasma levels of all lipids were either decreased or showed a tendency to be decreased by SARM‐2f. TE decreased the triglyceride level and increased the low‐density lipoprotein cholesterol level. Liver marker levels were not changed by either SARM‐2f or TE. Our data demonstrated that SARM‐2f exerted anabolic effects and produced a lipid profile that differed from that produced by testosterone in monkeys, suggesting that SARM‐2f might be useful for diseases such as sarcopenia.

show abstract

Section: Discussionmentioning

confidence: 95%

“…It is currently unclear whether the level of Lp (a), a potent risk factor for heart disease, is suppressed by statins, a widely used class of hydroxymethylglutaryl‐CoA reductase inhibitors . SARM‐2f showed a tendency to reduce blood Lp (a) levels in monkeys.…”

Section: Discussionmentioning

confidence: 99%

A selective androgen receptor modulator SARM‐2f activates androgen receptor, increases lean body mass, and suppresses blood lipid levels in cynomolgus monkeys

Morimoto

Yamaoka

Hara

2020

Pharmacology Res & Perspec

View full text Add to dashboard Cite

show abstract

“…Clinically, metabolic site and metabolic mechanisms of LP (a) in vivo remain unclear, and racial genetic factors have a greater impact on them. A number of studies have shown that atherosclerotic disease is closely related to LP (a), and LP (a) rise is an independent risk factor for cardiovascular events (Fan et al, 2017, Xu et al, 2017).…”

Section: Discussionmentioning

confidence: 99%

Modeling analysis of the relationship between atherosclerosis and related inflammatory factors

Zhang

Yuan

et al. 2017

Saudi Journal of Biological Sciences

View full text Add to dashboard Cite

To establish early diagnosis model of inflammatory factors for atherosclerosis (AS), providing theoretical evidence for early detection of AS and development of plaques. Serum samples were collected to detect the inflammatory factors including CysC, Hcy, hs-CRP, UA, FIB, D-D, LP (a), IL-6, SAA, sCD40L and MDA. Using Logistic regression analysis, the inflammatory factors used for modeling were screened out, and then the AS early diagnosis models were established based on receiver operating characteristic (ROC) curve, support vector machine and BP neural network respectively. No significant difference exists between the general materials of two groups. All 11 inflammatory factors had higher level in AS group than in control group. As shown in ROC curve, all inflammatory factors were helpful in AS diagnosis. In terms of sensitivity, UA ranked first (98) and FIB ranked last (55.5); in terms of specificity, UA ranked first (99) and FIB ranked last (78); in terms of area under the curve, UA and SAA ranked first (both were 0.995) and FIB ranked last (0.721). Based on Logistic regression equation, six factors were screened out, including Hcy, Hs-CRP, IL-6, D-D, CysC and MDA. According to classification, the final sixth steps had a prediction accuracy of 99%. When six inflammatory factors included in Logistic regression equation were detected jointly, the sensitivity, specificity and area under the curve were 57%, 97% and 0.821 respectively, while those of the model excluding D-D were 64%, 90% and 0.828, generally superior to results of joint detection including six factors. The ROC curve based on Hcy, Hs-CRP and MDA had a sensitivity of 87%, a specificity of 94% and an area under the curve of 0.869, being inferior to those of the ROC curve based on IL-6, D-D and Cys C, which were 87%, 92% and 0.936 respectively. The accuracy of SVM-AS diagnosis model and BP neural network model were 82.5% and 77.5% respectively. All 11 inflammatory factors are valuable in AS diagnosis. AS early diagnosis models based on Logistic regression analysis, ROC curve, support vector machine and BP neural network possess diagnostic value and can provide reference for clinical diagnosis.

show abstract

“…In the case of statins, there are conflicting findings regarding their effect on Lp(a) levels. Some studies have shown that statins are effective in lowering Lp(a) levels [ 119 , 120 ], while others have indicated an increase in Lp(a) of 10–20% [ 121 , 122 ]. There are also studies showing no effect of statins on Lp(a) levels [ 123 ].…”

Section: Currently Available Therapies Affecting Lp(a) Levelsmentioning

confidence: 99%

Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels

Sosnowska,

Stepinska,

Mitkowski

et al. 2024

Arch Med Sci

View full text Add to dashboard Cite

Elevated Lp(a) levels ≥50 mg/dl are estimated to occur in more than 1.5 billion people worldwide. However, determination of Lp(a) levels is performed far too rarely, including Poland, where, in fact, it is only since the 2021 PoLA guidelines that Lp(a) measurements have begun to be performed. Determination of Lp(a) concentrations is not easy due to, among other things, the different sizes of the apo(a) isoforms; however, the currently available certified tests make it possible to distinguish between people with low and high cardiovascular risk with a high degree of precision. In 2022, the first guidelines for the management of patients with elevated Lp(a) levels were published by the EAS and the AHA. The first Polish guidelines are the result of the work of experts from the two scientific societies and their aim is to provide clear, practical recommendations for the determination and management of elevated Lp(a) levels.

show abstract

Long-term statin therapy could be efficacious in reducing the lipoprotein (a) levels in patients with coronary artery disease modified by some traditional risk factors

Cited by 8 publications

References 37 publications

A selective androgen receptor modulator SARM‐2f activates androgen receptor, increases lean body mass, and suppresses blood lipid levels in cynomolgus monkeys

A selective androgen receptor modulator SARM‐2f activates androgen receptor, increases lean body mass, and suppresses blood lipid levels in cynomolgus monkeys

Modeling analysis of the relationship between atherosclerosis and related inflammatory factors

Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels

Contact Info

Product

Resources

About